MONARCH 2:阿贝西利联合氟维司群用于内分泌治疗进展后的HR+/HER2-晚期乳腺癌女性
MONARCH 2是一项全球双盲III期研究,纳入669例内分泌治疗进展后的HR+/HER2-晚期乳腺癌女性,按2:1随机接受阿贝西利或安慰剂(150 mg每日两次)联合氟维司群(500 mg)。阿贝西利联合氟维司群较单用氟维司群显著延长无进展生存期(中位16.4 vs 9.3个月;HR 0.553;95%CI 0.449-0.681;P<.001),可测量病灶患者的客观缓解率为48.1% vs 21.3%。
要点
- 阿贝西利联合氟维司群较单用氟维司群显著延长无进展生存期(中位16.4 vs 9.3个月;HR 0.553)。
- 可测量病灶患者中,阿贝西利联合氟维司群客观缓解率为48.1% vs 21.3%。
- 阿贝西利组最常见不良事件为腹泻(86.4% vs 24.7%)、中性粒细胞减少(46.0% vs 4.0%)。
核心结论
- 阿贝西利150 mg每日两次联合氟维司群在内分泌治疗进展后的HR+/HER2-晚期乳腺癌女性中有效,显著改善无进展生存期和客观缓解率,并显示可耐受的安全性。
研究设计与样本
- MONARCH 2为全球、双盲、III期研究,纳入在内分泌治疗期间进展的HR+/HER2-晚期乳腺癌女性。
- 患者按2:1随机接受阿贝西利或安慰剂(150 mg每日两次)连续给药联合氟维司群(500 mg,按说明书)。
- 主要终点为研究者评估的无进展生存期,关键次要终点包括总生存期、客观缓解率、缓解持续时间、临床获益率、生活质量和安全性。
- 2014年8月至2015年12月间共669例患者随机分配至阿贝西利联合氟维司群组(n=446)或安慰剂联合氟维司群组(n=223)。
主要发现
- 阿贝西利联合氟维司群较单用氟维司群显著延长无进展生存期(中位16.4 vs 9.3个月;HR 0.553;95%CI 0.449-0.681;P<.001)。
- 可测量病灶患者中,阿贝西利联合氟维司群客观缓解率为48.1%(95%CI 42.6%-53.6%),对照组为21.3%(95%CI 15.1%-27.6%)。
- 阿贝西利组与安慰剂组最常见不良事件分别为腹泻(86.4% vs 24.7%)、中性粒细胞减少(46.0% vs 4.0%)、恶心(45.1% vs 22.9%)和疲乏(39.9% vs 26.9%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC). Patients and Methods MONARCH 2 was a global, double-blind, phase III study of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), ≤ 12 months from the end of adjuvant ET, or while receiving first-line ET for metastatic disease. Patients were randomly assigned 2:1 to receive abemaciclib or placebo (150 mg twice daily) on a continuous schedule and fulvestrant (500 mg, per label). The primary end point was investigator-assessed progression-free survival (PFS), and key secondary end points included overall survival, objective response rate (ORR), duration of response, clinical benefit rate, quality of life, and safety. Results Between August 2014 and December 2015, 669 patients were randomly assigned to receive abemaciclib plus fulvestrant (n = 446) or placebo plus fulvestrant (n = 223). Abemaciclib plus fulvestrant significantly extended PFS versus fulvestrant alone (median, 16.4 v 9.3 months; hazard ratio, 0.553; 95% CI, 0.449 to 0.681; P < .001). In patients with measurable disease, abemaciclib plus fulvestrant achieved an ORR of 48.1% (95% CI, 42.6% to 53.6%) compared with 21.3% (95% CI, 15.1% to 27.6%) in the control arm. The most common adverse events in the abemaciclib versus placebo arms were diarrhea (86.4% v 24.7%), neutropenia (46.0% v 4.0%), nausea (45.1% v 22.9%), and fatigue (39.9% v 26.9%). Conclusions Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who progressed while receiving ET.
引用
- Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017. PMID: 28580882. doi:10.1200/JCO.2017.73.7585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。